Vertex Pharmaceuticals
VRTX
518 hedge funds and large institutions have $29.5B invested in Vertex Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 75 funds opening new positions, 192 increasing their positions, 182 reducing their positions, and 45 closing their positions.
67% more first-time investments, than exits
New positions opened: 75 | Existing positions closed: 45
20% more capital invested
Capital invested by funds: $24.5B → $29.5B (+$5B)
5% more funds holding
Funds holding: 494 → 518 (+24)
5% more repeat investments, than reductions
Existing positions increased: 192 | Existing positions reduced: 182
24% less call options, than puts
Call options by funds: $88.4M | Put options by funds: $117M
38% less funds holding in top 10
Funds holding in top 10: 8 → 5 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$463M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$174M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$170M |
| 4 |
JP Morgan Chase
New York
|
+$137M |
| 5 |
AIM
abrdn Investment Management
Edinburgh,
United Kingdom
|
+$94.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$324M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
-$236M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$198M |
| 4 |
MCM
Marsico Capital Management
Denver,
Colorado
|
-$195M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$69M |
VRTX Hedge Fund Activity: Q4 2015 in Review
518 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q4 2015, worth a combined $29.5B — up 20% from $24.5B a quarter earlier.
Buyers outnumbered sellers: 75 funds opened new VRTX positions and 45 closed out — a net gain of 30 holders — while 192 added to existing stakes and 182 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $463M. The largest seller was Fidelity Investments, cutting an estimated $324M.
- 518 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q4 2015, up from 494 in Q3 2015.
- Funds reported $29.5B of Vertex Pharmaceuticals stock for Q4 2015, up 20% quarter-over-quarter.
- 75 funds opened new Vertex Pharmaceuticals positions in Q4 2015 and 45 closed out, a net change of +30 holders.
- The largest Vertex Pharmaceuticals buyer in Q4 2015 was T. Rowe Price Associates, an estimated $463M added.
- The largest Vertex Pharmaceuticals seller in Q4 2015 was Fidelity Investments, an estimated $324M sold.
Based on aggregated 13F filings for Q4 2015.